Four peptide hormones decrease the number of human breast adenocarcinoma cells

European Journal of Clinical Investigation

Volumn 35, Issue 1, 2005, Pages 60-69

  Vesely, B A ^a   Song, S ^a   Sanchez Ramos, J ^a   Fitz, S R ^a   Solivan, S M ^a   Gower Jr , W R ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atrial natriuretic peptides; Cancer cell proliferation; Cell cycle progression; Cyclic GMP; DNA synthesis

Indexed keywords

8 BROMO CYCLIC GMP; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C; PEPTIDE HORMONE; UNCLASSIFIED DRUG; VESSEL DILATOR;

ARTICLE; BREAST ADENOCARCINOMA; CARCINOMA CELL; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; DNA; FEMALE; GUANYLATE CYCLASE; HORMONES; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 13244253639     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01444.x     Document Type: Article

References (38)

1. Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991;60:229-55.
2. Gardner DG, Kovacic-Milivojevic BK, Garmai M. Molecular biology of the natriuretic peptides. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost;1997.pp. 15-38.
3. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
4. Vesely DL, Morris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-8.
5. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-F1408.
6. 2. J Clin Invest 1992;89:1411-7.
7. Benjamin BA, Peterson TV. Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-R1355.
8. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
9. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-70.
10. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol, 2001;280:R1510-R1517.
11. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-34.
12. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-40.
13. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
14. Vesely DL., Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall; 1992. pp. 1-256.
15. Barr CS, Rhodes P, Struthers AD. C-type natriuretic peptide. Peptides 1996;17:1243-51.
16. Lainchbury J, Richards AM, Nicholls MG. Brain natriuretic peptide in heart failure. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost; 1997. pp. 151-8.
17. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-F177.
18. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
19. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989;192:230-5.
20. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998;58:205-16.
21. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-8.
22. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-7.
23. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-34.
24. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
25. Rashed HM, Sun H, Patel TB. Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology 1993;17:677-84.
26. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR Jr. Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004;34:674-82.
27. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 1977;57:3664-8.
28. Gratzner HG. Monoclonal antibody to 5-bromo-ad 5-lodo-deoxyuridine. A new reagent for detection of DNA replication. Science 1982;218:474-5.
29. Yu CCW, Woods AL, Levison DA. The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J 1992;24:121-31.
30. Morstyn G, Pyke K, Gardner J, Ashcroft R, deFazio A, Bhathal P. Immunohistochemical identification of proliferatory cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 1986;34:697-701.
31. Qin Y, Williams G. Comparison of the classical autoradiographic and immunohistochemical methods with BrdU for measuring proliferation parameters in colon cancer. Anticancer Res 1993;13:731-6.
32. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-4.
33. Vesely DL. Signal transduction: Activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-23.
34. Pitchumoni CS. Pancreatic disease. In: Stein JH, editor. Internal Medicine. St Louis: Mosby; 1998. pp. 2233-47.
35. Wolff RA, Abbruzzese JY, Evans DB. Neoplasms of the exocrine pancreas. In: Holland JF, Frei E III, editors. Cancer Medicine. London, UK: BC Decker Inc.; 2003. pp. 1585-614.
36. Osborne CK. Breast cancer. In: Stein JH, editor. Internal Medicine. St. Louis: Mosby; 1998. pp. 706-13.
37. Pelletier G. Localization of binding sites for ANF in the rat mammary gland. Peptides 1987;9:673-5.
38. Cvek K, Ridderstrale Y, Gerstberger R. Functional receptors for atrial natriuretic peptide in rat mammary gland during lactation. Endocrinology 1998;139:2615-21.